Impact of Science: "Past, Present, & Future of Personalized Medicine"

The Office of Graduate Education and the School of Medicine present to you, "Impact of Science: Past, Present, & Future of Personalized Medicine." This event is an oriented symposium and panel discussion open to the public, involving several well-known UNC alumni: Hutton Kearney, PhD, FACMG; Peter Mohler, PhD; and Steven Belinsky, PhD.

When May 17, 2013
from 03:00 PM to 05:00 PM
Where Hanes Art Center Auditorium
Contact Name
Contact Phone (919) 843-9910
Add event to calendar vCal
iCal
Our three presenters are UNC Alumni who have graciously accepted our invitation to speak at this event. They include:
Hutton Kearney, PhD, FACMG
Director, Cytogenetics Laboratory; Associate Director, Molecular Genetics Laboratory, Fullerton Genetics Center, Mission Health
Dr. Kearney was a Curriculum in Genetics and Molecular Biology student who got her PhD in Tom Petes’ lab in 2001, studying mechanisms of meiotic recombination in budding yeast. During her post-doctoral work (also at UNC) she was awarded an NRSA fellowship; she did a Fellowship in Human Cytogenetics and Molecular Genetics in the UNC Bryson Program in Human Genetics. After receiving board certification in clinical cytogenetics and molecular genetics from the American Board of Medical Genetics, she took a position as Assistant Director of the Clinical Molecular Diagnostics Laboratory at Duke University Health System. There Dr. Kearney began to develop emerging technologies for clinical uses, becoming an international leader in the use of microarray technologies for diagnostic purposes. Dr. Kearney is currently at Mission Health in Asheville, NC, where she has continued her research while also serving in a clinical role as Cytogenetics Director and Molecular Genetics Laboratory Associate Director. She also has been appointed Adjunct Assistant Professor in the Department of Genetics at UNC.
Peter Mohler, PhD
Director, Dorothy M. Davis Heart and Lung Research Institute; Professor, Departments of Internal Medicine (Division of Cardiovascular Medicine) and Physiology & Cell Biology; Associate Dean for Basic Research, The Ohio State University Medical Center
Dr. Mohler was a Cell and Molecular Physiology graduate student who got his PhD in Sharon Milgram’s lab in 2000 working on characterization of apical targeting mechanisms in polarized epithelial cells. After his postdoctoral training with HHMI at Duke University, he was first an assistant professor in pathology at Vanderbilt University, then accepted a faculty position with the University of Iowa Carver College of Medicine where he most recently served as Distinguished Associate Professor of Cardiovascular Medicine and Associate Professor of Internal Medicine and Molecular Physiology & Biophysics. In 2011 he was recruited to serve as the Director of the Dorothy M. Davis Heart and Lung Institute at Ohio State. His research is at the forefront of understanding the genetic and molecular basis for inherited and acquired cardiac arrhythmias. He is an Established Investigator of the American Heart Association, a Kavli Scholar of the U.S. National Academy of Sciences and a Pew Scholar.
Steven Belinsky, PhD
Vice President for Academic Research; Director, Lung Cancer Program; Senior Scientist, Lovelace Respiratory Research Institute
Dr. Belinsky was the very first graduate of UNC’s Curriculum in Toxicology when he received his PhD in 1984. He then did a postdoctoral fellowship and was a Senior Staff fellow at the National Institute of Environmental Health Sciences before moving to the Lovelace Respiratory Research Institute in Albuquerque, NM in 1990. He is currently Vice President for Research, Director of the Lung Cancer Program, and co-directs the Cancer Population Sciences Program for the University of New Mexico Cancer Center. Key findings from his laboratory include, identifying the p16 tumor suppressor gene as an early event in lung, the detection of promoter methylation of specific genes up to 3 years prior to diagnosis of lung cancer, and the demonstration that inhibitors that block promoter hypermethylation can prevent lung cancer development. Currently, his research is focused on controlling lung cancer through the identification of gene targets and pathways that are disrupted during the development of this disease. These findings are translated into population-based studies for the purpose of developing intermediate biomarkers for predicting cancer risk, early detection, prognosis, and response to preventive interventions.
Please mark your calendars and join us in participating in this one-of-a-kind opportunity!

More information about this event…